Boehringer Ingelheim Press Releases

New Global Campaign Aims to Prevent As Many As 1 Million Atrial Fibrillation-Related Strokes

Sub-Analysis Shows Primary Benefits seen with RE-LY® are Independent of Level of Centre-Based International Normalized Ratio Control

Boehringer Ingelheim celebrates its 125-year
existence and looks to the future with confidence

Boehringer Ingelheim inaugurates the Shanghai “Center of Competence” as a part of the company’s EUR 100 million expansion project in China

Boehringer Ingelheim successfully concluded the purchase of Fort Dodge cattle vaccines for its Mexican business

Turnover and profit expectations fulfilled for first half-year results / New growth expected from innovative medicines

European Committee for Medicinal Products for Human Use (CHMP) adopts Positive Opinion for TWYNSTA®, Boehringer Ingelheim’s new single pill combination hypertension treatment

VERxVE study demonstrates efficacy and safety of 400mg once daily nevirapine (Viramune®) extended release (NVP XR) formulation

First PCV-2 / Mycoplasma hyopneumoniae vaccine combination registered in the European Union

Fekrije Selimi wins Boehringer Ingelheim’s FENS Award 2010 for Exceptional Research in Neuroscience

Metacam® for pigs now also available as oral suspension

Boehringer Ingelheim launches PCV2 vaccine in Russia

Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile

Boehringer Ingelheim announces results of phase III data showing that linagliptin significantly lowered blood glucose with an excellent safety and tolerability profile

Boehringer Ingelheim receives European approval for two new strengths for the once daily tablet formulation of Mirapexin®/Sifrol® prolonged-release for the treatment of Parkinson’s disease

Boehringer Ingelheim Comments on June 18th FDA Advisory Committee Meeting

Boehringer Ingelheim affirms safety of telmisartan with an analysis of 50,000 patients and strongly disagrees with the publication of Sipahi et al in Lancet Oncology June 2010

Dabigatran etexilate as effective and safe as enoxaparin in preventing venous thromboembolism (VTE) after total hip replacement surgery and significantly reduced the combined endpoint of major VTE and VTE-related death